Compass Pathways (NASDAQ:CMPS) Trading 8% Higher After Analyst Upgrade

Posted by on Jun 26th, 2026

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report) rose 8% on Friday after Canaccord Genuity Group raised their price target on the stock from $18.00 to $20.00. Canaccord Genuity Group currently has a buy rating on the stock. Compass Pathways traded as high as $14.48 and last traded at $14.6640. 1,449,858 shares changed hands during trading, a decline of 60% from the average daily volume of 3,588,450 shares. The stock had previously closed at $13.58.

A number of other brokerages also recently commented on CMPS. TD Cowen restated a “buy” rating on shares of Compass Pathways in a research note on Monday, June 1st. Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Wolfe Research started coverage on Compass Pathways in a research note on Friday, May 22nd. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Compass Pathways in a research note on Friday, May 22nd. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Compass Pathways presently has an average rating of “Buy” and a consensus target price of $23.10.

View Our Latest Research Report on CMPS

Hedge Funds Weigh In On Compass Pathways

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CMPS. Corient Private Wealth LLC grew its stake in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after acquiring an additional 1,200 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares in the last quarter. Conservest Capital Advisors Inc. increased its position in shares of Compass Pathways by 24.6% during the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after purchasing an additional 5,000 shares during the period. Persistent Asset Partners Ltd acquired a new position in shares of Compass Pathways in the fourth quarter valued at $38,000. Finally, Raymond James Financial Inc. lifted its holdings in shares of Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after acquiring an additional 6,228 shares during the period. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Stock Up 8.2%

The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of -4.65 and a beta of 2.50. The business has a fifty day simple moving average of $10.80 and a two-hundred day simple moving average of $8.07. The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Equities analysts expect that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Compass Pathways Company Profile

(Get Free Report)

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

Read More

Receive News & Ratings for Compass Pathways Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Pathways and related companies with MarketBeat.com's FREE daily email newsletter.